Subscribe To
MBIO / Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
MBIO News
By GlobeNewsWire
September 7, 2023
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focu more_horizontal
By Zacks Investment Research
June 13, 2023
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in p more_horizontal
By Zacks Investment Research
May 26, 2023
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
The mean of analysts' price targets for Mustang Bio, Inc. (MBIO) points to a 711.6% upside in the stock. While this highly sought-after metric has not more_horizontal
By GuruFocus
May 17, 2022
Caribou Charges Ahead on Study Results
Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that more_horizontal
By GlobeNewsWire
April 4, 2022
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focu more_horizontal
By Benzinga
January 25, 2022
FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru more_horizontal
By Benzinga
January 25, 2022
FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru more_horizontal
By Benzinga
January 25, 2022
FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder
The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Dru more_horizontal